8月12日 - ** 药物研发公司Absci（ABSI.O）股价下跌1.4%，收于9.3美元
** 该公司公布第二季度营收为31.8万美元，远低于分析师预期的120万美元
** 报告显示，研发支出从去年的2,050万美元增至2,260万美元，主要受ABSI内部项目推进的推动
** 券商TD Cowen表示，由于合作款项和里程碑付款减少，预计营收将几乎减半，这凸显了该公司对合作伙伴资助收入的依赖
** TD Cowen表示，投资者正将关注点转向预计将于今年晚些时候公布的ABS-201脱发治疗数据
** 10家券商中有9家给予该股“买入”或更高评级，1家给予“持有”评级；目标价中位数为14美元——LSEG数据
** 计入当日涨幅在内，该股今年以来股价已翻了一番多
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.